Last reviewed: July 2, 2026

Last updated: July 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide has become one of the most studied weight loss medications in recent years, with robust clinical data showing meaningful results for most users. The STEP trials (Semaglutide Treatment Effect in People with Obesity) demonstrated that participants achieved average weight reductions ranging from 10% to 22% of their starting body weight, depending on the dose and study duration. Understanding realistic expectations—and how your individual genetics may influence your response—helps set the foundation for successful long-term weight management.

Clinical Trial Results for Semaglutide Weight Loss

The landmark STEP 1 trial published in 2021 followed over 1,800 adults with obesity for 68 weeks. Participants receiving the highest maintenance dose (2.4 mg weekly) achieved an average weight loss of 14.9% of their starting body weight, compared to 2.4% in the placebo group. At the 1.7 mg dose, average losses were approximately 10.2%, while the 0.4 mg dose produced roughly 4.6% reduction. These differences highlight how semaglutide's effects scale across different therapeutic doses.

STEP 2 and STEP 3 trials extended these findings to people with type 2 diabetes and those with cardiovascular disease history. In STEP 2, participants maintained an average weight loss of 9.6% at 2.4 mg weekly over 120 weeks, suggesting that benefits persist with continued treatment. STEP 3 enrolled over 600 people already on a weight loss maintenance program; those receiving semaglutide 2.4 mg lost 17.4% body weight compared to 3.4% in controls. These real-world conditions more closely mirror how many patients actually use the medication alongside lifestyle changes.

Why Weight Loss Results Vary Between Individuals

Your genetic makeup influences how your body responds to semaglutide and related GLP-1 medications. Key genetic variations in the GLP1R gene (such as rs6923761) and GIPR gene (rs1800437) affect receptor sensitivity and signaling efficiency. Similarly, variants in the FTO gene (rs9939609) and MC4R gene (rs17782313) play roles in appetite regulation and metabolic rate. Two people taking the same semaglutide dose may experience notably different appetite suppression and weight loss trajectories based on these underlying genetic differences.

Beyond genetics, adherence to dosing schedules, diet quality, physical activity levels, baseline body composition, and metabolic health conditions all shape individual outcomes. Stress levels, sleep quality, medications you're already taking, and even your starting body weight percentage influence the rate and total magnitude of weight loss. This complexity underscores why a one-size-fits-all approach often falls short—personalization based on your unique biology and lifestyle produces superior results.

How PlexusDx Personalizes Semaglutide Therapy

PlexusDx offers compounded semaglutide injection starting at $149 per month from licensed 503A compounding pharmacies, making high-quality GLP-1 therapy accessible without insurance or membership fees. The medication is HSA/FSA eligible, further reducing out-of-pocket costs for many patients. By removing financial barriers, PlexusDx ensures consistent access so you can maintain the regular dosing schedule necessary for optimal results.

The optional Precision Peptide Genetic Test ($99 add-on after your first month) maps 14 metabolic pathways and 150+ genetic insights related to peptide response, appetite control, and weight regulation. This test identifies your individual genetic predispositions—helping PlexusDx physicians understand whether you're likely a rapid responder, standard responder, or slow responder to semaglutide. Based on these insights, your clinician can optimize your starting dose, titration schedule, and potential combination therapy (such as the dual-compound GLP-Squared injection) to maximize your weight loss potential from day one.

Realistic Expectations and Timeline for Semaglutide Success

Most people begin noticing appetite suppression and early weight loss within the first 2-4 weeks of semaglutide treatment, though significant weight reduction typically becomes measurable over 8-12 weeks. The dose titration phase—where your injected dose gradually increases every four weeks—continues for about 16-20 weeks in standard protocols. Meaningful weight loss of 5-10% of starting body weight often occurs during this initial ramp-up period, with continued improvements over subsequent months of treatment.

Sustaining weight loss requires ongoing medication adherence; clinical data shows that weight regain occurs when semaglutide is discontinued without transitioning to lifestyle maintenance strategies. The good news is that semaglutide's appetite-suppressing effects give you a powerful window to rebuild healthier eating patterns and establish consistent exercise habits that persist even if medication is eventually tapered. PlexusDx emphasizes that your dose may need adjustment as your body adapts—your price won't, maintaining flat monthly costs regardless of dose level so you can optimize therapy without financial penalties.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically expect to lose on semaglutide?

Clinical trials show average weight loss of 10-15% of body weight at standard doses, with some participants achieving 20% or more. Your individual result depends on genetics, adherence, diet quality, and exercise consistency. PlexusDx's Precision Peptide Genetic Test can reveal your genetic predisposition for response, helping optimize your personalized protocol.

How long does it take to see weight loss results on semaglutide?

Most users notice appetite suppression within 1-2 weeks and measurable weight loss within 4-8 weeks. Significant results—5-10% body weight reduction—typically appear over the first 12-16 weeks as your dose reaches therapeutic levels. Continued improvements often extend over 6-12 months of consistent treatment.

Is compounded semaglutide as effective as brand-name Wegovy?

Semaglutide from licensed 503A compounding pharmacies contains the identical active ingredient, mechanism, and potency as Wegovy. Clinical efficacy is equivalent when manufactured under FDA quality standards. PlexusDx's compounded semaglutide injection starts at $149/month, offering significant cost savings without compromise on effectiveness.

What happens to weight loss if I stop taking semaglutide?

Clinical evidence shows gradual weight regain when semaglutide is discontinued, as appetite and metabolic rate normalize. However, the lifestyle changes and healthier eating patterns you establish during treatment often provide lasting benefit. PlexusDx supports long-term therapy with flat pricing across all doses, so cost won't force premature discontinuation.

Can genetic testing predict how much weight I'll lose on semaglutide?

The PlexusDx Precision Peptide Genetic Test identifies genetic variants in GLP1R, GIPR, FTO, and MC4R that influence your response potential. While genetics are powerful predictors, they don't determine outcome alone—lifestyle factors matter equally. This genetic insight lets your PlexusDx clinician tailor your initial dose, titration pace, and combination therapy strategies to match your unique biology.

Related Reading

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves